Axsome Therapeutics, Inc.

This Phase 2 trial tested AXS-12 (reboxetine) in 21 adults with narcolepsy and cataplexy. Participants received either the drug or a placebo for three weeks, then switched. The goal was to see if AXS-12 could reduce weekly cataplexy attacks and improve excessive daytime sleepines…

This study tested an experimental drug called AXS-12 (reboxetine) in 90 people with narcolepsy who experience cataplexy (sudden muscle weakness) and excessive daytime sleepiness. Participants took either the drug or a placebo twice daily for several weeks. The main goal was to se…

This Phase 3 trial tested whether solriamfetol, a drug already approved for sleep disorders, can reduce ADHD symptoms in adults. Over 500 participants took either a daily dose of solriamfetol or a placebo for six weeks. The study measured changes in attention and hyperactivity us…

This Phase 3 trial tested a single dose of AXS-07, a combination of meloxicam and rizatriptan, for treating migraines in adults. 302 participants took either the drug or a placebo at the first sign of migraine pain. The study measured how many were pain-free and free of their mos…

This study tested a drug called solriamfetol in 59 adults with obstructive sleep apnea who also had trouble thinking clearly and felt very sleepy during the day. The goal was to see if the drug could improve cognitive function, like attention and processing speed. Participants to…

This Phase 3 trial tested whether solriamfetol, a drug used for sleepiness, can safely ease depression symptoms in adults with major depressive disorder. 346 participants received either solriamfetol or a placebo daily. Researchers measured changes in depression scores and tracke…

This study looked at the long-term safety and effectiveness of a drug called AXS-05 for treating agitation in people with Alzheimer's disease. A total of 456 participants who had already been in earlier studies took part. The goal was to see if the drug could safely reduce agitat…

This study tested a new drug called AXS-07, which combines meloxicam and rizatriptan, for treating migraine attacks in adults. The 100 participants had previously not gotten enough relief from oral CGRP inhibitors. The goal was to see if the drug could relieve headache pain and o…

This study tested an experimental drug called AXS-05 to see if it can safely reduce agitation in people with Alzheimer's disease. About 408 participants took either the drug or a placebo for several weeks. The goal was to measure changes in agitation using a standard rating scale…

This study looked at the long-term safety and effectiveness of a drug called AXS-12 for people with narcolepsy who also have sudden muscle weakness (cataplexy) and severe daytime sleepiness. 68 people who had already completed an earlier study took AXS-12 and were monitored for s…